Clinical Trial Update: Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating venetoclax with either ibrutinib or acalabrutinib in high-risk chronic lymphocytic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• IMBRUVICA (IBRUTINIB)
• Venclyxto (Venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: RECRUITING